Baid Smita K, Rubino Domenica, Sinaii Ninet, Ramsey Sheila, Frank Arthur, Nieman Lynnette K
The Program in Reproductive and Adult Endocrinology, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1109, USA.
J Clin Endocrinol Metab. 2009 Oct;94(10):3857-64. doi: 10.1210/jc.2008-2766. Epub 2009 Jul 14.
Recent reports suggest a higher prevalence (1-5%) of Cushing's syndrome in certain patient populations with features of the disorder (e.g., diabetes), but the prevalence in the overweight and obese population is not known.
The aim of the study was to evaluate the diagnostic performance of screening tests for Cushing's syndrome in overweight and obese subjects with at least two other features of the disorder.
We conducted a cross-sectional prospective study.
A total of 369 subjects (73% female) completed two or three tests: a 24-h urine cortisol, and/or late-night salivary cortisol, and/or 1 mg dexamethasone suppression test (DST). If any result was abnormal [based on laboratory reference range or cortisol after DST > or = 1.8 microg/dl (50 nmol/liter)], tests were repeated and/or a dexamethasone-CRH test was performed. Subjects with abnormal DST results and a low dexamethasone level were asked to repeat the test with 2 mg of dexamethasone.
In addition to obesity, subjects had a mean of five to six features of Cushing's syndrome. None was found to have Cushing's syndrome. Test specificities to exclude Cushing's syndrome for subjects who completed three tests were: urine cortisol, 96% [95% confidence interval (CI), 93-98%]; DST, 90% (95% CI, 87-93%); salivary cortisol, 84% by RIA (95% CI, 79-89%) and 92% by liquid chromatography-tandem mass spectrometry (95% CI, 88-95%). The combined specificity (both tests normal) for all combinations of two tests was 84 to 90%, with overlapping CIs.
These data do not support widespread screening of overweight and obese subjects for Cushing's syndrome; test results for such patients may be falsely abnormal.
近期报告显示,在某些具有该疾病特征(如糖尿病)的患者群体中,库欣综合征的患病率较高(1%-5%),但超重和肥胖人群中的患病率尚不清楚。
本研究旨在评估超重和肥胖且至少具有该疾病其他两种特征的受试者中库欣综合征筛查试验的诊断性能。
我们进行了一项横断面前瞻性研究。
共有369名受试者(73%为女性)完成了两项或三项检测:24小时尿皮质醇检测,和/或午夜唾液皮质醇检测,和/或1毫克地塞米松抑制试验(DST)。如果任何一项结果异常[基于实验室参考范围或DST后皮质醇>或 = 1.8微克/分升(50纳摩尔/升)],则重复检测和/或进行地塞米松-促肾上腺皮质激素释放激素试验。DST结果异常且地塞米松水平较低的受试者被要求用2毫克地塞米松重复该试验。
除肥胖外,受试者平均具有五到六种库欣综合征特征。未发现有库欣综合征患者。完成三项检测的受试者排除库欣综合征的检测特异性分别为:尿皮质醇,96%[95%置信区间(CI),93%-98%];DST,90%(95%CI,87%-93%);唾液皮质醇,放射免疫分析为84%(95%CI,79%-89%),液相色谱-串联质谱分析为92%(9%CI,88%-95%)。两项检测所有组合的联合特异性(两项检测均正常)为84%-90%,置信区间有重叠。
这些数据不支持对超重和肥胖受试者广泛筛查库欣综合征;此类患者的检测结果可能会出现假异常。